ACE-031: The Myostatin Inhibitor & Muscle Research Protocol
Disclaimer: ACE-031 (Ramatercept) is an investigational fusion protein. It is not FDA-approved and was historically discontinued in clinical trials due to safety concerns (minor bleeding). This article is for laboratory research purposes only, reflecting data from 2024–2026 studies.
What is ACE-031?
ACE-031 is a soluble "decoy" receptor. It is a fusion protein consisting of the extracellular portion of the Activin Receptor Type IIB (ActRIIB) fused to the Fc portion of human IgG1.
In the body, certain proteins like Myostatin and Activin A act as "brakes" on muscle growth. ACE-031 works by floating in the bloodstream and "trapping" these proteins before they can reach your muscle cells and signal them to stop growing.
- Mechanism: Ligand Trap / Myostatin Antagonist.
- Target: Myostatin, Activin A, Activin B, and GDF-11.
- Primary Research Goal: Massive hypertrophy (muscle growth) and increased bone mineral density.
Mechanism of Action: Releasing the Brakes
Muscle mass is governed by a delicate balance of "growth" signals (like IGF-1) and "stop" signals (like Myostatin). ACE-031 shifts this balance dramatically:
- Ligand Binding: ACE-031 binds to circulating Myostatin with high affinity.
- Competitive Inhibition: By acting as a decoy receptor, it prevents Myostatin from binding to the actual receptors on the muscle fiber.
- Unchecked Hypertrophy: With the "stop" signal blocked, the muscle undergoes rapid protein synthesis and fiber enlargement (especially Type II fast-twitch fibers).
- Bone Crosstalk: In 2026 research, ACE-031 is also noted for increasing bone density by inhibiting the same pathways that limit osteoblast (bone-building) activity.
The "Safety Pause": Epistaxis & Telangiectasias
In original human trials (Duchenne Muscular Dystrophy), ACE-031 research was halted.
- The Issue: Subjects experienced minor nosebleeds (epistaxis) and small dilated blood vessels on the skin (telangiectasias).
- The Reason: ACE-031 is "promiscuous"—it doesn't just bind to Myostatin; it also binds to BMP9, a protein essential for vascular (blood vessel) structural integrity.
- Current Status: Modern 2026 research often uses lower, "pulsed" doses to try and achieve muscle growth without triggering these vascular side effects.
Research Protocols (1mg Vial)
ACE-031 is a large, complex protein with a long half-life (10–15 days). Unlike small peptides that require daily injections, ACE-031 is researched with infrequent dosing.
Reconstitution (1 mL BAC Water)
For a 1 mg vial, adding 1 mL of Bacteriostatic Water (BAC) is the standard for precise measurement.
Total Vial: 1,000 mcg (1 mg)
Concentration: 1,000 mcg per 1 mL (10 mcg per unit)
Research Dosing Roadmap (Subcutaneous)
| Research Level | Single Dose | Syringe Units (IU) | Frequency |
| Micro-Pulse | 100 mcg | 10 Units | Once Weekly |
| Introductory | 250 mcg | 25 Units | Once Weekly |
| Standard | 1,000 mcg (1mg) | 100 Units | Once every 2 weeks |
2026 Observation: Many researchers find that a 1mg vial is a "single-use" dose for a standard 2-week research window.
Frequently Asked Questions
Does it work better than Follistatin?
ACE-031 is generally considered more "systemic" and potent than Follistatin 344, as it targets a broader range of inhibitory ligands (Activins and GDFs).
Will it cause permanent muscle growth?
No. Once the peptide clears the system (approx. 3–4 weeks after the last dose), Myostatin levels return to normal, and the "brakes" are reapplied.
Is it stable?
ACE-031 is a very large, fragile protein. Do not shake the vial after adding water. It must be kept refrigerated at all times. Once reconstituted, it should be used within 7–10 days for maximum efficacy.
Why is it banned in sports?
ACE-031 is strictly prohibited by WADA (World Anti-Doping Agency) under "Hormone and Metabolic Modulators" because it provides a significant, non-natural advantage in muscle mass and strength.
Summary Checklist
- [ ] 1 Vial ACE-031 (1 mg).
- [ ] 1 mL Bacteriostatic Water.
- [ ] Subcutaneous injection (Once every 7–14 days).
- [ ] Monitor: Watch for any signs of skin redness or minor capillary breakage (red spots).
About PeptideDosing.co: We synthesize current research literature on peptide compounds for educational purposes. We do not sell peptides. Always consult qualified researchers and comply with local regulations.